Physician profile
Benjamin Wayne Light
NPI 1760463632
$3,744.54
in general payments reported to CMS, 2019-2025
25 companies · $632 in 2025
The $632 reported for 2025 was more than what a typical Otolaryngology/Facial Plastic Surgery provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $298 · 2020: $219 · 2021: $479 · 2022: $754 · 2023: $618 · 2024: $745 · 2025: $632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,904 · Education: $90.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,904.37 |
| Education | $90.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $626.82 | 2019-2025 | Dupixent |
| Allergan, INC. | $525.46 | 2019-2022 | |
| Genzyme Corporation | $498.99 | 2020-2025 | |
| Glaxosmithkline, LLC. | $415.06 | 2021-2025 | Nucala |
| Optinose US, INC. | $403.87 | 2019-2024 | |
| Merz North America, INC. | $228.54 | 2019-2025 | Xeomin |
| Abbvie INC. | $223.62 | 2023-2025 | |
| Acclarent, INC | $196.53 | 2019-2023 | Trudi Nav Cable |
| Aerin Medical INC. | $161.38 | 2020-2024 | |
| Stryker Corporation | $102.39 | 2019-2024 | Xpress Loprofile |
| Amgen INC. | $58.88 | 2025 | Tezspire |
| Revance Therapeutics, INC. | $50.30 | 2025 | Daxxify |
| Integra Lifesciences Corporation | $34.62 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $24.79 | 2025 | Exparel |
| Heron Therapeutics, INC. | $21.23 | 2024 | Aponvie |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurent Medical Limited | $20.87 | 2025 | Neuromark Radiofrequency Console, Neuromark System |
| Hikma Pharmaceuticals USA | $20.31 | 2023 | Ryaltris |
| Merck Sharp & Dohme LLC | $18.93 | 2023 | |
| Olympus America INC. | $17.95 | 2024 | Soltive |
| Astrazeneca Pharmaceuticals Lp | $17.87 | 2025 | Tezspire |
| Kaleo, INC. | $16.60 | 2023 | Auvi-Q |
| Convatec INC. | $15.79 | 2023 | |
| Paratek Pharmaceuticals, INC. | $15.35 | 2025 | Xhance |
| Medtronic, INC. | $14.71 | 2024 | Propel |
| Intersect Ent, INC. | $13.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Light listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.